摘要
目的:探讨晚期胃癌化疗期间联合肠内营养治疗的价值。方法:本研究为前瞻性随机研究。按NRS 2002营养风险量表筛选具有营养不良风险的62例不可手术的晚期胃癌病人随机分为两组。两组病人均行奥沙利铂联合替吉奥化疗,对照组(n=30)在化疗的同时予营养咨询;治疗组(n=32)在化疗的同时予安素肠内营养治疗,所有病人在化疗前和化疗后行NRS 2002量表评估,观察并记录体重、体重指数、血清白蛋白,化疗结束后评价化疗疗效与不良反应。结果:化疗结束后肠内营养组血清白蛋白水平、体重及体重指数明显高于对照组(P<0.05),两组病人化疗后不良反应和化疗疗效差别无统计学意义。结论:肠内营养联合化疗可改善晚期胃癌病人的营养状态,降低营养不良风险。
Objective: To investigate the effects of enteral nutrition support in inoperable advanced gastric cancer patients during chemotherapy. Methods: This was a prospective randomized study. A total of 62 patients with advanced gastric cancer were firsted evaluated according to the Nutritional Risk Screening 2002(NRS 2002)scale, and were randomly divided into two groups. All patients received oxaliplatin combined with tegefur gimeracil oteraci. Patients in the control group(n = 30) received chemotherapy along with nutrition consultation, and patients in the treatment group(n = 32) were provided enteral nutrition-additionally. NRS 2002 assessment was conducted before and after chemotherapy. The body weight, BMI, serum albumin, and the efficacy and toxicity were collected during the study.Results: Patients in the treatment group had significantly higher serum albumin levels, body weight and BMI than those of the control group(P〈0.05). No differences were found as for the efficacy and toxicity of chemotherapy between two groups. Conclusion: Enteral nutrition support therapy can improve the nutrition status of gastric cancer patients who received chemotherapy and reduce the risk of malnutrition.
作者
蔡铭泉
汤玮玮
安汉祥
李晓虹
CAI Ming-quan TANG Wei-wei AN Han-xiang LI Xiao-hong(Department of Medical Oncology, Xiamen Cancer Hospital, The First Affiliated Hospital of Xiamen University, Xiamen 361000, Fujian, China)
出处
《肠外与肠内营养》
北大核心
2017年第4期205-208,共4页
Parenteral & Enteral Nutrition
关键词
晚期胃癌
肠内营养
化疗
营养风险筛查NRS
2002
Advanced gastric cancer
Enteral nutrition
Chemotherapy
Nutritional Risk Screening 2002